Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Seer, Inc.NASDAQ: SEER

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items dips below year-ago levels

Q1 FY2026 other non-cash items of $2.48M fell 28.3% year over year, behind the +15.1% change in trailing-twelve-month other non-cash items. Sequentially, it rose 24.9% from the prior quarter. Over 3 fiscal years it compounded at +62.1% a year.

Context

  • Other non-cash items amounted to 43.9% of revenue in FY2025, down 0.9 pp from a year earlier.
  • Other non-cash items increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -28.3% toward the trailing-twelve-month pace of +15.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.48M+24.9% QoQ
Last fiscal yearDec 2025
$7.07M+13.1% YoY
LTMMar 2026
$8.38M+15.1% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-28.3%——
1 year+13.1%——
3-year CAGR+62.1%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
7.07M USD
Year-over-year change
+13.1%
4-year CAGR
+62.9%

Other Non-Cash Items vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so other non-cash items is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.1% is the 10th highest of 19, against a peer median of +42.6%.
  • Other non-cash items amounts to 55.7% of revenue for SEER, versus a peer median of 31.1%.
SEER Competitors
Other Non-Cash Items for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$184.14M USD+2614.2%+147.8%—
SANASana Biotechnology, Inc.LTM Mar 2026$91.96M USD+300.7%——
LYELLyell Immunopharma, Inc.LTM Mar 2026$67.8M USD-43.9%+0.8%218706.5%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$22.91M USD+92.3%—3.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$17.54M USD+931.6%+25.6%50.3%
PHVSPharvaris N.V.LTM Sep 2026€8.96M EUR-641.3%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$8.77M USD-7.1%-20.3%31.1%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$8.47M USD-59.3%—8.1%
SEERSeer, Inc.LTM Mar 2026$8.38M USD+15.1%+62.1%55.7%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$4.77M USD-67.0%-71.6%—
MOLNMolecular Partners AGLTM Mar 2026CHF 4.3M CHF+257.9%——
PEPGPepGen Inc.LTM Mar 2026$2.6M USD+225.7%——
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$2.1M USD-47.0%—4.9%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$1.26M USD+181.6%——
STTKShattuck Labs, Inc.LTM Mar 2026$1M USD-10.0%—100.3%
MNOVMediciNova, Inc.LTM Mar 2026$873.86K USD+415.7%+2.1%146.5%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$708K USD-73.1%+20.3%—
QSIQuantum-Si incorporatedLTM Mar 2026$569K USD+107.2%—30.7%
NKTXNkarta, Inc.LTM Mar 2026$561K USD-88.1%-9.8%—
Peer median (excluding SEER) —+42.6%+1.4%31.1%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.